Skip to main content

Advertisement

Log in

A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Culy CR, Clemett D, Wiseman LR (2000) Oxaliplatin: a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60:895–924

    Article  PubMed  CAS  Google Scholar 

  2. de Gramont A, Figer A, Seymour H, Homerin H, Hmissi A, Cassidy J et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan R, Williamson SK et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Article  PubMed  CAS  Google Scholar 

  4. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and preventive measures. Semin Oncol 29:21–33

    Article  PubMed  CAS  Google Scholar 

  5. Grothey A (2003) Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30[Suppl 4]:5–13

    Article  PubMed  CAS  Google Scholar 

  6. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter HK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexitability. J Clin Oncol 20:1767–1774

    Article  PubMed  CAS  Google Scholar 

  7. Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O et al. (1997) Autoantibodies detected to expressed K channels are implicated in neuromyotonia. Ann Neurol 41:238–246

    Article  PubMed  CAS  Google Scholar 

  8. Nagado T, Arimura K, Sonoda Y et al (1999) Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain 122:2057–2066

    Article  PubMed  Google Scholar 

  9. Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A (2005) Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 146:1027–1039

    Article  PubMed  CAS  Google Scholar 

  10. Frei E, Spindler I, Grissmer S, Jager H (2006) Interactions of N-terminal and C-terminal parts of the small conductance Ca2+ activated K+ channels, hSK3. Cell Physiol Biochem 18:165–176

    Article  PubMed  CAS  Google Scholar 

  11. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate H, Gamelin E (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated channels. J Neurophysiol 85:2293–2297

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carlo Barone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basso, M., Cassano, A., Modoni, A. et al. A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance. Eur J Clin Pharmacol 64, 739–741 (2008). https://doi.org/10.1007/s00228-008-0474-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-008-0474-x

Keywords

Navigation